ADVERTISEMENT
Fed. Circ. Judge Unsure IP At Heart Of $1.1B Juno Win Is Valid
Law360 (July 6, 2021, 8:46 PM EDT) The Federal Circuit s chief judge appeared receptive Tuesday to Kite Pharma s argument that a Juno Therapeutics drug patent is too broad to be valid, potentially calling into question Juno s more than $1.1 billion infringement win during the appellate court s first in-person hearing since the arrival of the COVID-19 pandemic.
The three-judge panel was considering Kite Pharma Inc. s appeal of a California federal judge s final judgment, which tacked $389 million in enhanced damages onto a $752 million jury verdict that found Kite willfully infringed Juno s patent with its own immunotherapy cancer drug, Yescarta.
China s first CAR-T Cell Therapy approved-Fosun Kite Axicabtagene Ciloleucel (FKC876)
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Kite Joint Venture - Fosun Kite - Gains the First CAR T-cell Therapy Approval in China
gilead.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gilead.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
ResearchAndMarkets.com s offering.
CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as living drugs.
T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is then used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. These receptors are synthetic and do not exist naturally. Once infused into the patient, these CARs enable the T-cells to recognize and get attached to an an
Ginkgo agrees to $17.5b merger with Harry Sloanâs SPAC
By Gillian Tan, Crystal Tse and Kristen V. Brown Bloomberg,Updated May 11, 2021, 7:31 a.m.
Email to a Friend
An automated fermenting machine at the Ginkgo Bioworks Inc. facility in Boston.Scott Eisen/Bloomberg
Ginkgo Bioworks Inc., which calls itself an âorganism designâ company, has agreed to go public in a $17.5 billion merger with a blank-check firm backed by former Hollywood executive Harry Sloan.
The Boston-based company, which uses technology to program cells for a potentially wide variety of uses, will combine with Soaring Eagle Acquisition Corp., according to a regulatory filing Tuesday that confirmed an earlier Bloomberg News report.